<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39395617</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3064</ISSN><JournalIssue CitedMedium="Internet"><Volume>234</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Respiratory medicine</Title><ISOAbbreviation>Respir Med</ISOAbbreviation></Journal><ArticleTitle>Favorable impact of azithromycin on patients in the intensive care unit with coronavirus disease 2019: Insights from the first wave using a Japanese database.</ArticleTitle><Pagination><StartPage>107834</StartPage><MedlinePgn>107834</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmed.2024.107834</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0954-6111(24)00309-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Azithromycin has favorable effects on critical respiratory diseases owing to its antimicrobial and anti-inflammatory properties. During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, azithromycin was frequently administered before specific treatments were developed. However, the efficacy of this treatment has not been verified. We retrospectively investigated the effects of its intravenous (IV) administration in patients with severe/critical COVID-19 using the National Administrative Database of Japan during the first wave (February-April 2020).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were categorized based on whether they received IV azithromycin within three days of hospitalization. An overlap weighting method with estimated propensity scores was used to reduce bias.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 830 patients with severe/critical COVID-19, 148 (17.8 %) received azithromycin, and 682 (82.2 %) did not. After adjustment, the use of azithromycin was associated with a shorter duration of intensive care unit (ICU) management (-3.48 days, 95 % confidence interval [CI]: 4.59 to -2.38). However, other endpoints, including mortality rate, duration of mechanical ventilation, and duration of hospital stay, did not suggest any associations. Furthermore, of the 115 ICU patients, 27 (23.5 %) were treated with IV azithromycin and 88 (76.5 %) were not. After adjustment, azithromycin was associated with favorable outcomes, including reduced in-hospital mortality (odds ratio [OR], 0.45, 95 % CI: 0.22 to 0.92), 30-day mortality (OR, 0.46, 95 % CI: 0.22 to 0.94), and a shorter duration of ICU management (-2.94 days, 95 % CI: 5.15 to -0.73).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We verified that IV azithromycin was associated with favorable impact in patients with COVID-19 requiring ICU management.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tokito</LastName><ForeName>Takatomo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kido</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan. Electronic address: t-kido@nagasaki-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Shuntaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan; Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyashita</LastName><ForeName>Ritsuko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozasa</LastName><ForeName>Mutsumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuno</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yura</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takemoto</LastName><ForeName>Shinnosuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takazono</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan; Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishimoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Noriho</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obase</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishimatsu</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nursing, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishino</LastName><ForeName>Tomoya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fushimi</LastName><ForeName>Kiyohide</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumikawa</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan; Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukae</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Med</MedlineTA><NlmUniqueID>8908438</NlmUniqueID><ISSNLinking>0954-6111</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Azithromycin</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hiroshi Mukae reports a relationship with Pfizer Japan Inc that includes: speaking and lecture fees. Koichi Izumikawa reports a relationship with Pfizer Japan Inc that includes: speaking and lecture fees. Takahiro Takazono reports a relationship with Pfizer Japan Inc that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39395617</ArticleId><ArticleId IdType="doi">10.1016/j.rmed.2024.107834</ArticleId><ArticleId IdType="pii">S0954-6111(24)00309-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>